中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
4期
195-196,202
,共3页
重症肌无力%中西医结合%强肌健力饮
重癥肌無力%中西醫結閤%彊肌健力飲
중증기무력%중서의결합%강기건력음
Myasthenia gravis%Integrative medicine%Qiangji Jianli Yin
目的:研究中西医结合在重症肌无力危象中的应用价值。方法选择2009年4月~2011年12月我院收治的重症肌无力危象患者76例,按照不同的治疗方法分成研究组(38例)与对照组(38例),研究组运用中西医结合方案治疗,对照组采用常规性治疗方案。比较两组治疗效果。结果研究组患者与对照组患者在治疗前、治疗后的绝对评分分值比较差异有统计学意义(P<0.01),研究组患者与对照组患者危象持续时间比较差异有统计学意义(P<0.01)。研究组的总有效率为89.5%,显著优于对照组(P<0.05)。结论中西医结合治疗在重症肌无力危象中应用价值较高,可以较好地改善预后,降低死亡率。
目的:研究中西醫結閤在重癥肌無力危象中的應用價值。方法選擇2009年4月~2011年12月我院收治的重癥肌無力危象患者76例,按照不同的治療方法分成研究組(38例)與對照組(38例),研究組運用中西醫結閤方案治療,對照組採用常規性治療方案。比較兩組治療效果。結果研究組患者與對照組患者在治療前、治療後的絕對評分分值比較差異有統計學意義(P<0.01),研究組患者與對照組患者危象持續時間比較差異有統計學意義(P<0.01)。研究組的總有效率為89.5%,顯著優于對照組(P<0.05)。結論中西醫結閤治療在重癥肌無力危象中應用價值較高,可以較好地改善預後,降低死亡率。
목적:연구중서의결합재중증기무력위상중적응용개치。방법선택2009년4월~2011년12월아원수치적중증기무력위상환자76례,안조불동적치료방법분성연구조(38례)여대조조(38례),연구조운용중서의결합방안치료,대조조채용상규성치료방안。비교량조치료효과。결과연구조환자여대조조환자재치료전、치료후적절대평분분치비교차이유통계학의의(P<0.01),연구조환자여대조조환자위상지속시간비교차이유통계학의의(P<0.01)。연구조적총유효솔위89.5%,현저우우대조조(P<0.05)。결론중서의결합치료재중증기무력위상중응용개치교고,가이교호지개선예후,강저사망솔。
Objective To explore the clinical value of applying integrative medicine on myasthenia gravis crisis. Methods 76 patients with myasthenia gravis crisis admitted and treated in our hospital from Apr 2009 to Dec 2011 were selected and assigned to the research group (38 cases) and the control group (38 cases) according to therapeutic methods. The research group was treated by integrative medicine while the control group was treated by conventional methods. The therapeutic effects were compared between the two groups. Results There research group and the control had difference in absolute scoring before and after treatment (P<0.01). The research group and the control had difference in duration of myasthenia gravis crisis (P < 0.01). The total effective rate of the research group was 89.5%, significantly higher than the control group (P<0.05). Conclusion Integrative medicine has high clinical value on treatment of myasthenia gravis crisis. Integrative medicine can improve prognosis and reduce the mortality rate.